* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for TCM Biotech International's PEG Ratio or its related term are showing as below:
ROCO:4169'
s PEG Ratio Range Over the Past 10 Years
Min: 1.46 Med: 2.72 Max: 301.25
Current: 262.37
During the past 13 years, TCM Biotech International's highest PEG Ratio was 301.25. The lowest was 1.46. And the median was 2.72.
ROCO:4169's PEG Ratio is ranked worse than 99.1% of 111
companies
in the Biotechnology industry
Industry Median: 1.49
vs ROCO:4169: 262.37
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
TCM Biotech International PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of TCM Biotech International's PEG Ratio
For the Biotechnology subindustry, TCM Biotech International's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TCM Biotech International's PEG Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TCM Biotech International's PEG Ratio distribution charts can be found below:
* The bar in red indicates where TCM Biotech International's PEG Ratio falls into.
TCM Biotech International PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
TCM Biotech International (ROCO:4169) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
TCM Biotech International PEG Ratio Related Terms
Thank you for viewing the detailed overview of TCM Biotech International's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
TCM Biotech International (ROCO:4169) Business Description
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in the research and development of therapeutics for the prevention and treatment of liver diseases. Its products includes Anti-adhesion System, Anti-neoplastic agents, Osteoporosis Treatment Preparation, Iron Preparations, Osteoarthritis (OA) Treatment Products, Urinary System Treatment Products and others. The company has a business presence in Taiwan and other international countries such as the United States, Japan, Singapore, Malaysia, Vietnam, the Philippines and China. The entity derives key revenue from the sales of multiple medical products which includes medicine, medical device, functional food and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:4169 has been successfully added to your 